Highlights

  • GSK shares showed limited short-term pressure while maintaining sizable gains over longer periods.
  • Broker assessments indicate upside potential despite recent share price consolidation.
  • RAPT Therapeutics acquisition adds a late-stage immunology asset with extended dosing potential.

GSK plc (LSE:GSK) Closed at 1,813.22 GBX on 19 January, the stock slipped 2.78 GBX, or 0.15%, during the session. On a monthly basis, performance remains largely stable, with a modest gain of 0.18%.

Despite near-term fluctuations, the stock has recorded notable appreciation over extended horizons. GSK shares have risen 34.91% over the past six months and 33.92% over the past year, indicating sustained investor interest over medium- and long-term periods. These gains contrast with recent volatility and suggest that broader market participants continue to factor in the company’s pipeline developments and core business visibility.

Market Sentiment and Broker Views
Research coverage reflects a largely positive stance on GSK’s outlook. Jefferies reiterated a Buy rating on 20 January 2026, setting a price target of 2,100 GBX, which implies an upside of 15.64% from the recent closing level.

Separately, Rothschild & Co Redburn, through analyst Bakker Simon P., reaffirmed a Buy recommendation on 19 January 2026. The firm assigned a higher price target of 2,570 GBX, representing a potential upside of 41.52%. These assessments suggest that analysts continue to view the company’s valuation as supported by its longer-term earnings visibility and pipeline progress, even as the share price consolidates in the near term.

RAPT Therapeutics Acquisition Details
GSK gained investor's attention today following this this update on definitive agreement to acquire RAPT Therapeutics, a US-based clinical-stage biopharmaceutical company focused on inflammatory and immunologic diseases. The deal values RAPT’s equity at approximately USD 2.2 billion, with GSK agreeing to pay USD 58.00 per share in cash, translating to an upfront investment of about USD 1.9 billion, net of cash acquired.

The transaction provides GSK with global rights to ozureprubart, excluding certain Asian territories. The company will also assume milestone and royalty obligations linked to RAPT’s partner agreements. Completion of the acquisition is expected in the first quarter of 2026, subject to regulatory and shareholder approvals.

Pipeline Context and Clinical Timeline
Ozureprubart is a long-acting anti-immunoglobulin E monoclonal antibody in Phase IIb development for the prophylactic treatment of food allergies. IgE is associated with approximately 94% of severe food allergy reactions, while currently available anti-IgE therapies typically require injections every two to four weeks.

Ozureprubart is designed for 12-week dosing, which may reduce treatment frequency. Phase IIb prestIgE trial data are expected in 2027, with Phase III trials planned for both adult and paediatric populations thereafter. In the US, more than 17 million people are diagnosed with food allergies, with severe reactions contributing to over 3 million hospital and emergency visits annually.